These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 30176566)

  • 1. Lipoprotein-apheresis in familial hypercholesterolemia: Long-term patient compliance in a French cohort.
    Beliard S; Gallo A; Duchêne E; Carrié A; Bittar R; Chapman MJ; Bruckert E; Saheb S
    Atherosclerosis; 2018 Oct; 277():66-71. PubMed ID: 30176566
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A nation-wide survey of patients with homozygous familial hypercholesterolemia phenotype undergoing LDL-apheresis in Turkey (A-HIT 1 registry).
    Kayikcioglu M; Tokgozoglu L; Yilmaz M; Kaynar L; Aktan M; Durmuş RB; Gokce C; Temizhan A; Ozcebe OI; Akyol TK; Okutan H; Sag S; Gul OO; Salcioglu Z; Yenercag M; Altunkeser BB; Kuku I; Yasar HY; Kurtoglu E; Kose MD; Demircioglu S; Pekkolay Z; Ilhan O
    Atherosclerosis; 2018 Mar; 270():42-48. PubMed ID: 29407887
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High serum triglyceride concentrations in patients with homozygous familial hypercholesterolemia attenuate the efficacy of lipoprotein apheresis by dextran sulfate adsorption.
    Drouin-Chartier JP; Tremblay AJ; Bergeron J; Lamarche B; Couture P
    Atherosclerosis; 2018 Mar; 270():26-32. PubMed ID: 29407885
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term lipoprotein apheresis in the treatment of severe familial hypercholesterolemia refractory to high intensity statin therapy: Three year experience at a lipoprotein apheresis centre.
    Mickiewicz A; Borowiec-Wolna J; Bachorski W; Gilis-Malinowska N; Gałąska R; Raczak G; Chmara M; Wasąg B; Jaguszewski MJ; Fijałkowski M; Gruchała M
    Cardiol J; 2019; 26(6):669-679. PubMed ID: 30234904
    [TBL] [Abstract][Full Text] [Related]  

  • 5. What have we learned from Turkish familial hypercholesterolemia registries (A-HIT1 and A-HIT2)?
    Kayikcioglu M; Tokgozoglu L; Dogan V; Ceyhan C; Tuncez A; Kutlu M; Onrat E; Alici G; Akbulut M; Celik A; Yesilbursa D; Sahin T; Sonmez A; Ozdogan O; Temizhan A; Kilic S; Bayram F; Sabuncu T; Coskun FY; Ildizli M; Durakoglugil E; Kirilmaz B; Yilmaz MB; Yigit Z; Yildirim AB; Gedikli O; Topcu S; Oğuz A; Demir M; Yenerçağ M; Yıldırır A; Demircan S; Yilmaz M; Kaynar LG; Aktan M; Durmus RB; Gokce C; Ozcebe Oİ; Akyol TK; Okutan H; Sag S; Gul OO; Salcioglu Z; Altunkeser BB; Kuku I; Yasar HY; Kurtoglu E; Kose MD; Demircioglu S; Pekkolay Z; Ilhan O; Can LH
    Atherosclerosis; 2018 Oct; 277():341-346. PubMed ID: 30270069
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Practice of lipoprotein apheresis and short-term efficacy in children with homozygous familial hypercholesterolemia: Data from an international registry.
    Luirink IK; Hutten BA; Greber-Platzer S; Kolovou GD; Dann EJ; de Ferranti SD; Taylan C; Bruckert E; Saheb S; Oh J; Driemeyer J; Farnier M; Pape L; Schmitt CP; Novoa FJ; Maeser M; Masana L; Shahrani A; Wiegman A; Groothoff JW
    Atherosclerosis; 2020 Apr; 299():24-31. PubMed ID: 32199148
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lipoprotein apheresis efficacy, challenges and outcomes: A descriptive analysis from the UK Lipoprotein Apheresis Registry, 1989-2017.
    Pottle A; Thompson G; Barbir M; Bayly G; Cegla J; Cramb R; Dawson T; Eatough R; Kale V; Neuwirth C; Nicholson K; Payne J; Scott J; Soran H; Walji S; Watkins S; Weedon H; Nath Datta DB
    Atherosclerosis; 2019 Nov; 290():44-51. PubMed ID: 31563836
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Low-Density Lipoprotein Receptor Genotype Is a Significant Determinant of the Rebound in Low-Density Lipoprotein Cholesterol Concentration After Lipoprotein Apheresis Among Patients With Homozygous Familial Hypercholesterolemia.
    Drouin-Chartier JP; Tremblay AJ; Bergeron J; Lamarche B; Couture P
    Circulation; 2017 Aug; 136(9):880-882. PubMed ID: 28847800
    [No Abstract]   [Full Text] [Related]  

  • 9. Pregnancy in homozygous familial hypercholesterolemia--Importance of LDL-apheresis.
    Blaha M; Lanska M; Blaha V; Boudys L; Zak P
    Atheroscler Suppl; 2015 May; 18():134-9. PubMed ID: 25936317
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multimodal lipid-lowering treatment in pediatric patients with homozygous familial hypercholesterolemia-target attainment requires further increase of intensity.
    Klaus G; Taylan C; Büscher R; Schmitt CP; Pape L; Oh J; Driemeyer J; Galiano M; König J; Schürfeld C; Spitthöver R; Schaefer JR; Weber LT; Heibges A; Klingel R
    Pediatr Nephrol; 2018 Jul; 33(7):1199-1208. PubMed ID: 29502162
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The lipid-lowering effects of lomitapide are unaffected by adjunctive apheresis in patients with homozygous familial hypercholesterolaemia - a post-hoc analysis of a Phase 3, single-arm, open-label trial.
    Stefanutti C; Blom DJ; Averna MR; Meagher EA; Theron Hd; Marais AD; Hegele RA; Sirtori CR; Shah PK; Gaudet D; Vigna GB; Sachais BS; Di Giacomo S; du Plessis AM; Bloedon LT; Balser J; Rader DJ; Cuchel M;
    Atherosclerosis; 2015 Jun; 240(2):408-14. PubMed ID: 25897792
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of circulating miRNAs in patients with familial hypercholesterolaemia treated by LDL/Lp(a) apheresis.
    Dlouha D; Blaha M; Blaha V; Fatorova I; Hubacek JA; Stavek P; Lanska V; Parikova A; Pitha J
    Atheroscler Suppl; 2017 Nov; 30():128-134. PubMed ID: 29096828
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of homozygous familial hypercholesterolaemia in paediatric patients: A monocentric experience.
    Buonuomo PS; Macchiaiolo M; Leone G; Valente P; Mastrogiorgio G; Gnazzo M; Rana I; Gonfiantini MV; Gagliardi MG; Romano F; Bartuli A
    Eur J Prev Cardiol; 2018 Jul; 25(10):1098-1105. PubMed ID: 29785886
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low-density lipoprotein apheresis as long-term treatment for children with homozygous familial hypercholesterolemia.
    Zwiener RJ; Uauy R; Petruska ML; Huet BA
    J Pediatr; 1995 May; 126(5 Pt 1):728-35. PubMed ID: 7751996
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current insights into the German lipoprotein apheresis standard: PCSK9-inhibitors, lipoprotein apheresis or both?
    Schettler VJJ; Ringel J; Jacob S; Julius U; Klingel R; Heigl F; Roeseler E; Grützmacher P;
    Atheroscler Suppl; 2017 Nov; 30():44-49. PubMed ID: 29096860
    [TBL] [Abstract][Full Text] [Related]  

  • 16. LDL apheresis improves coronary flow reserve on the left anterior descending artery in patients with familial hypercholesterolemia and chronic ischemic heart disease.
    Sampietro T; Sbrana F; Pasanisi EM; Bigazzi F; Petersen C; Coceani M; Dal Pino B; Ripoli A; Pianelli M; Luciani R
    Atheroscler Suppl; 2017 Nov; 30():135-140. PubMed ID: 29096829
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Statin intolerance in heterozygous familial hypercolesterolemia with cardiovascular disease: After PCSK-9 antibodies what else?
    Sbrana F; Dal Pino B; Bigazzi F; Ripoli A; Passino C; Gabutti A; Pasanisi EM; Petersen C; Valleggi A; Todiere G; Barison A; Giannoni A; Panchetti L; Becherini F; Pianelli M; Luciani R; Sampietro T
    Eur J Prev Cardiol; 2017 Sep; 24(14):1528-1531. PubMed ID: 28555526
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term outcome in 53 patients with homozygous familial hypercholesterolaemia in a single centre in France.
    Bruckert E; Kalmykova O; Bittar R; Carreau V; Béliard S; Saheb S; Rosenbaum D; Bonnefont-Rousselot D; Thomas D; Emery C; Khoshnood B; Carrié A
    Atherosclerosis; 2017 Feb; 257():130-137. PubMed ID: 28131047
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Three different schedules of low-density lipoprotein apheresis compared with plasmapheresis in patients with homozygous familial hypercholesterolemia.
    Berger GM; Firth JC; Jacobs P; Wood L; Marais AD; Horak A
    Am J Med; 1990 Feb; 88(2):94-100. PubMed ID: 2105647
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical management, psychosocial characteristics, and quality of life in patients with homozygous familial hypercholesterolemia undergoing LDL-apheresis in Turkey: Results of a nationwide survey (A-HIT1 registry).
    Kayikcioglu M; Kuman-Tunçel O; Pirildar S; Yílmaz M; Kaynar L; Aktan M; Durmuş RB; Gökçe C; Temizhan A; Özcebe OI; Akyol TK; Okutan H; Sağ S; Oz Gul O; Salcioglu Z; Yenercag M; Altunkeser BB; Kuku I; Yasar HY; Kurtoğlu E; Demir M; Demircioğlu S; Pekkolay Z; Ílhan O; Tokgozoglu L
    J Clin Lipidol; 2019; 13(3):455-467. PubMed ID: 30928440
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.